ANAB · AnaptysBio Inc
United States · RS rating 51 · As of 2026-11-03
| Price | 47.73 USD |
|---|---|
| 1-day change | +1.8% |
| RS rating (overall / 1M / 3M / 12M) | 51 / 49 / 40 / 94 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 45 / 37 / 54 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +203.8% |
| Sales growth Q/Q | +41.8% |
| Distance from 52-week high | +31.6% |
| Market cap (USD) | $1.5B |